Overview

Simvastatin Therapy for Moderate and Severe COPD

Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do not have other indications for statin treatment.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Canadian Institutes of Health Research (CIHR)
National Heart, Lung, and Blood Institute (NHLBI)
Ottawa Hospital Research Institute
Treatments:
Simvastatin